As the med tech industry casts its eye toward quick, point-of-care diagnostics, scientists at MIT are teaming up with physicians from Harvard Medical School to create new technology that could help distinguish between acute emphysema and heart failure by measuring an individual's breath.
Amid efforts to quell the growing Ebola epidemic, scientists, companies and health officials are teaming up to develop innovative medical devices to treat the deadly disease.
Fremont, CA's Shockwave Medical released clinical trial data at the Vascular Interventional Advances Annual Conference in Las Vegas that it says demonstrate the effectiveness of its investigational Lithoplasty balloon catheters at treating peripheral artery disease.
Drones are used to kill bad guys in war zones, but graduate student Alex Momont wants to use them to save lives. He has developed a prototype drone capable of flying to the rescue of heart attack victims by delivering a defibrillator to the site much faster than an ambulance.
Gene therapy startup Spark Therapeutics has picked up the FDA's coveted breakthrough-therapy designation for its lead candidate, a one-time treatment that promises a permanent solution some rare eye diseases.
Tolero Pharmaceuticals has pocketed a second tranche of its Series B funding round, netting $22.4 million in total as it prepares to take its expirimental marrow cancer treatment into late-stage development.
Researchers at Imperial College London have created an artificial cell with separate compartments that can communicate with one another via chemical reactions, much the way, for instance, the nucleus would communicate with other parts of the cell.
AstraZeneca's ovarian cancer-treating olaparib may also have a beneficial effect on prostate cancer, researchers said, potentially increasing the value of a key drug in the company's self-appraised $12 billion oncology pipeline.
Maryland's Technology Development Corp. is dishing out funds for startups and early stage digital health companies. Overall, 15 med tech companies received a total of $1.5 million.
Regeneron is pouring more money than ever into its well-respected R&D operation, spending big on a cadre of late-stage candidates the Big Biotech believes can outshine its blockbuster eye treatment.